The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
Approximately 20% of unselected cases and 30% cytogenetically diploid cases of acute myeloid leukemia (AML) and 80% of grade II-III gliomas and secondary glioblastomas carry mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. IDH1/2 mutations prevent oxidative decarboxylation of isocitrat...
Main Authors: | Dinesh eRakheja, L Jeffrey Medeiros, Scott eBevan, Weina eChen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00169/full |
Similar Items
-
Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
by: Raffaela S. Berger, et al.
Published: (2021-04-01) -
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
by: Luyan Mu, et al.
Published: (2018-03-01) -
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
by: Lizhen Liu, et al.
Published: (2021-01-01) -
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
by: Rémi Longuespée, et al.
Published: (2018-03-01) -
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
by: Cara Reiter-Brennan, et al.
Published: (2018-12-01)